A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
Clinical Pharmacology in Drug Development · 2026-05 · 15 (5)
DOI: 10.1002/cpdd.70061 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 30.04.2026. Verfasst von Wei Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacometrics, Johnson & Johnson, Raritan, NJ, USA. Hauptthemen laut MEDLINE: Pyrazoles, Quinoxalines, Liver Diseases, Receptors, Fibroblast Growth Factor. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson, LLC.
Abstract (Originalsprache)
Erdafitinib, an oral pan‐ FGFR inhibitor is extensively metabolized in the liver. This open‐label, single‐dose, phase 1 study evaluated the pharmacokinetics (PK) of erdafitinib in participants with hepatic impairment versus healthy controls. Overall, 26 participants were enrolled. Following a single 6 mg oral dose, the maximum plasma concentration (C max ) of total erdafitinib was reached at median t max of 3 h across all groups (participants with mild hepatic impairment, moderate hepatic impairment, and control). The geometric mean ratios for free C max and free AUC ∞ , were 96.07% and 95.22% in participants with mild hepatic impairment compared with controls, respectively. The geometric mean ratios for free C max and free AUC ∞ , were 104.8% and 87.51% in participants with moderate hepatic impairment compared with controls, respectively. Single oral doses of erdafitinib were well tolerated across all cohorts, and no new safety signals were noted. The results demonstrate that dose adjustments are not necessary in participants with mild or moderate hepatic impairment receiving oral erdafitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Pharmacometrics, Johnson & Johnson, Raritan, NJ, USA.
- Oncology Research & Development, Johnson & Johnson, Beerse, Belgium.
- Bioanalytical Discovery & Development Sciences, Johnson & Johnson, Beerse, Belgium.
- Statistics and Decision Science, Johnson & Johnson, Raritan, NJ, USA.
- Clinical Pharmacology & Pharmacometrics, Johnson & Johnson, Spring House, PA, USA.
Förderung
- Johnson & Johnson, LLC
Zitieren
APA
Zhu, W., Hellemans, P., Mitselos, A., De Meulder, M., Jiao, J. J., & Tian, H. (2026). A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor. Clinical Pharmacology in Drug Development, 15(5). https://doi.org/10.1002/cpdd.70061
Vancouver
Zhu W, Hellemans P, Mitselos A, De Meulder M, Jiao JJ, Tian H. A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor. Clinical Pharmacology in Drug Development. 2026;15(5). doi:10.1002/cpdd.70061
BibTeX
@article{Zhu2026,
author = {Zhu, Wei and Hellemans, Peter and Mitselos, Anna and De Meulder, Marc and Jiao, Juhui James and Tian, Hui},
title = {A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cpdd.70061}
}
EUVIMED